

# Martin R Stockler

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8997288/publications.pdf>

Version: 2024-02-01

109  
papers

5,305  
citations

109321

35  
h-index

95266

68  
g-index

111  
all docs

111  
docs citations

111  
times ranked

7721  
citing authors

#	ARTICLE	IF	CITATIONS
1	â€Painâ€™free TRUS Bâ€™™: a phase 3 doubleâ€™blind placeboâ€™controlled randomized trial of methoxyflurane with periprostatic local anaesthesia to reduce the discomfort of transrectal ultrasonographyâ€™guided prostate biopsy (ANZUP 1501). BJU International, 2022, 129, 591-600.	2.5	5
2	Clinical Trial Protocol for HyNOVA: Hyperthermic and Normothermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III epithelial OVArian, fallopian tube and primary peritoneal cancer (ANZGOG1901/2020). Journal of Gynecologic Oncology, 2022, 33, .	2.2	7
3	Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP) Tj ETQq1 1 0.784314 rgBT /Over 837-846.	1.6	29
4	External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer. Journal of Clinical Oncology, 2022, 40, 1772-1782.	1.6	9
5	Estimating prognosis in advanced cancer: Time to embrace uncertainty. Journal of Geriatric Oncology, 2022, 13, 389-390.	1.0	1
6	Reply to L. Marandino et al. Journal of Clinical Oncology, 2022, , JCO2200497.	1.6	0
7	Evaluation of a Mainstream Model of Genetic Testing for Men With Prostate Cancer. JCO Oncology Practice, 2021, 17, e204-e216.	2.9	27
8	Should I Have Adjuvant Immunotherapy? An Interview Study Among Adults with Resected Stage 3 Melanoma and Their Partners. Patient, 2021, 14, 635-647.	2.7	8
9	An Updated Systematic Review of Quantitative Studies Assessing Anxiety, Depression, Fear of Cancer Recurrence or Psychological Distress in Testicular Cancer Survivors. Cancer Management and Research, 2021, Volume 13, 3803-3816.	1.9	15
10	Patient-Reported Outcomes Associated with Treatments for Testicular Cancer: A Systematic Review. Patient Related Outcome Measures, 2021, Volume 12, 129-171.	1.2	10
11	Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy. European Urology, 2021, 80, 275-279.	1.9	28
12	RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse. Contemporary Clinical Trials, 2021, 108, 106482.	1.8	33
13	Adjuvant immunotherapy recommendations for stage III melanoma: physician and nurse interviews. BMC Cancer, 2021, 21, 1014.	2.6	3
14	Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase. EBioMedicine, 2021, 72, 103625.	6.1	23
15	Patientsâ€™™ Preferences for 3 Months vs 6 Months of Adjuvant Chemotherapy for Colon Cancer. JNCI Cancer Spectrum, 2021, 5, pkaa107.	2.9	2
16	Estimating survival time in older adults receiving chemotherapy for advanced cancer. Journal of Geriatric Oncology, 2020, 11, 617-625.	1.0	8
17	Preferences for Immunotherapy in Melanoma: A Systematic Review. Annals of Surgical Oncology, 2020, 27, 571-584.	1.5	36
18	Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial. Journal of Clinical Oncology, 2020, 38, 4064-4075.	1.6	78

#	ARTICLE	IF	CITATIONS
19	Tamoxifen for hepatocellular carcinoma. The Cochrane Library, 2020, 2020, CD001024.	2.8	1
20	Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. Lancet Oncology, The, 2020, 21, 1213-1223.	10.7	109
21	Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. New England Journal of Medicine, 2019, 381, 121-131.	27.0	982
22	Discussing Prognosis, Preferences, and End-of-Life Care in Advanced Cancer. JAMA Oncology, 2019, 5, 788.	7.1	4
23	Community views on factors affecting medicines resource allocation: cross-sectional survey of 3080 adults in Australia. Australian Health Review, 2019, 43, 254.	1.1	9
24	Predicting chemotherapy toxicity in older adults: Comparing the predictive value of the CARG Toxicity Score with oncologists' estimates of toxicity based on clinical judgement. Journal of Geriatric Oncology, 2019, 10, 202-209.	1.0	40
25	Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial. European Urology, 2019, 76, 306-312.	1.9	26
26	Oncologists' perceptions on the usefulness of geriatric assessment measures and the CARG toxicity score when prescribing chemotherapy for older patients with cancer. Journal of Geriatric Oncology, 2019, 10, 210-215.	1.0	6
27	The administration of patient-reported outcome questionnaires in cancer trials: Interviews with trial coordinators regarding their roles, experiences, challenges and training. Contemporary Clinical Trials Communications, 2018, 9, 23-32.	1.1	23
28	Screen Failure Rates in Contemporary Randomized Clinical Phase II/III Therapeutic Trials in Genitourinary Malignancies. Clinical Genitourinary Cancer, 2018, 16, e233-e242.	1.9	8
29	The importance of patient-reported outcomes in clinical trials and strategies for future optimization. Patient Related Outcome Measures, 2018, Volume 9, 353-367.	1.2	295
30	A randomised controlled trial of an advance care planning intervention for patients with incurable cancer. British Journal of Cancer, 2018, 119, 1182-1190.	6.4	54
31	Sentinel-Lymph-Node-Based Management or Routine Axillary Clearance? Five-Year Outcomes of the RACS Sentinel Node Biopsy Versus Axillary Clearance (SNAC) 1 Trial: Assessment and Incidence of True Lymphedema. Annals of Surgical Oncology, 2017, 24, 1064-1070.	1.5	33
32	Societal perspective on access to publicly subsidised medicines: A cross sectional survey of 3080 adults in Australia. PLoS ONE, 2017, 12, e0172971.	2.5	24
33	Valuing the benefits of new anticancer drugs. Medical Journal of Australia, 2016, 204, 403-405.	1.7	0
34	What is access to radiation therapy? A conceptual framework and review of influencing factors. Australian Health Review, 2016, 40, 11.	1.1	15
35	Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial. British Journal of Cancer, 2016, 115, 1179-1185.	6.4	19
36	Design, implementation and reporting strategies to reduce the instance and impact of missing patient-reported outcome (PRO) data: a systematic review. BMJ Open, 2016, 6, e010938.	1.9	87

#	ARTICLE	IF	CITATIONS
37	The prevalence, severity, and correlates of psychological distress and impaired health-related quality of life following treatment for testicular cancer: a survivorship study. <i>Journal of Cancer Survivorship</i> , 2016, 10, 223-233.	2.9	57
38	Patients' preferred and perceived roles in making decisions about adjuvant chemotherapy for non-small-cell lung cancer. <i>Lung Cancer</i> , 2016, 95, 8-14.	2.0	18
39	Screen failure rates in contemporary phase II/III therapeutic trials in genitourinary malignancies.. <i>Journal of Clinical Oncology</i> , 2016, 34, 176-176.	1.6	1
40	The impact of chemotherapy on cognition: A longitudinal study in testicular cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 487-487.	1.6	0
41	Barriers to radiotherapy utilisation in New South Wales Australia: Health professionals' perceptions of impacting factors. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2015, 59, 535-541.	1.8	16
42	Development and piloting of a decision aid for women considering participation in the Sentinel Node Biopsy versus Axillary Clearance 2 breast cancer trial. <i>Clinical Trials</i> , 2015, 12, 409-417.	1.6	8
43	Sentinel Lymph Node Based Management or Routine Axillary Clearance? Three-year Outcomes of the RACS Sentinel Node Biopsy Versus Axillary Clearance (SNAC) 1 Trial. <i>Annals of Surgical Oncology</i> , 2015, 22, 17-23.	1.5	22
44	Regional Variation in Identified Cancer Care Needs of Early-Career Oncologists in China, India, and Pakistan. <i>Oncologist</i> , 2015, 20, 532-538.	3.7	12
45	TROG 03.06 and VCOG PR 01-03: The "timing of androgen deprivation therapy in prostate cancer patients with a rising PSA (TOAD)" collaborative randomised phase III trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5007-5007.	1.6	3
46	Patients' preferences for adjuvant sorafenib after resection of intermediate or high-risk renal cell carcinoma in the SORCE trial: What makes it worthwhile?. <i>Journal of Clinical Oncology</i> , 2015, 33, 415-415.	1.6	2
47	Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised prostate cancer: The ANZUP ENZARAD Trial (ANZUP 1303).. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS5078-TPS5078.	1.6	0
48	Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer: the ANZUP ENZAMET Trial (ANZUP 1304).. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS5077-TPS5077.	1.6	0
49	Baseline predictors of early treatment failure in patients with platinum resistant/refractory (PRR) and potentially platinum sensitive (PPS ≥ 3) recurrent ovarian cancer (ROC) receiving ≥ 3 lines of chemotherapy: The Gynaecologic Cancer Intergroup (GCIG) Symptom Benefit Study (SBS).. <i>Journal of Clinical Oncology</i> , 2015, 33, 5564-5564.	1.6	0
50	Is it time to change the primary endpoint in clinical trials in recurrent ovarian cancer (ROC)? Symptom burden and outcomes in patients with platinum resistant/refractory (PRR) and potentially platinum sensitive ROC receiving ≥ 3 lines of chemotherapy (PPS ≥ 3)â€”The Gynecologic Cancer Intergroup (GCIG) Symptom Benefit Study (SBS).. <i>Journal of Clinical Oncology</i> , 2015, 33, 5536-5536.	1.6	1
51	Factors influencing the use of <sup>RT</sup> in <sup>NSW</sup>: A qualitative study exploring consumer and health professional perspectives. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2014, 58, 625-632.	1.8	13
52	Development of the Measure of Ovarian Symptoms and Treatment Concerns: Aiming for Optimal Measurement of Patient-Reported Symptom Benefit With Chemotherapy for Symptomatic Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 865-873.	2.5	30
53	Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1379-1388.	10.7	119
54	Patient-Reported Outcome Results From the Open-Label Phase III AURELIA Trial Evaluating Bevacizumab-Containing Therapy for Platinum-Resistant Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 1309-1316.	1.6	154

#	ARTICLE	IF	CITATIONS
55	Methylated glutathione s-transferase 1 (mGSTP1) as a potential plasma epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer (CRPC).. Journal of Clinical Oncology, 2014, 32, 11-11.	1.6	6
56	Circulating biomarkers and outcomes in a single-arm phase II trial of first-line sunitinib alternating with everolimus for advanced renal cell carcinoma (aRCC): EVERSUN ANZUP trial 0901.. Journal of Clinical Oncology, 2014, 32, 428-428.	1.6	1
57	EVERSUN: A phase II trial of everolimus alternating with sunitinib as first-line therapy for advanced renal cell carcinoma (aRCC) (ANZUP trial 0901).. Journal of Clinical Oncology, 2014, 32, 438-438.	1.6	0
58	Circulating microRNAs associated with docetaxel-resistant castration resistant prostate cancer.. Journal of Clinical Oncology, 2014, 32, 44-44.	1.6	0
59	Patterns of management and surveillance imaging amongst medical oncologists in Australia for stage I testicular cancer. BJU International, 2013, 112, E35-43.	2.5	14
60	A phase II clinical trial of the Vascular Disrupting Agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma. Lung Cancer, 2013, 81, 422-427.	2.0	51
61	Intravesical chemotherapy plus bacille Calmette-Guérin in non-muscle invasive bladder cancer: a systematic review with meta-analysis. BJU International, 2013, 111, 977-983.	2.5	43
62	Hope, Quality of Life, and Benefit From Treatment in Women Having Chemotherapy for Platinum-Resistant/Refractory Recurrent Ovarian Cancer: The Gynecologic Cancer Intergroup Symptom Benefit Study. Oncologist, 2013, 18, 1221-1228.	3.7	30
63	The Median Informs the Message: Accuracy of Individualized Scenarios for Survival Time Based on Oncologists' Estimates. Journal of Clinical Oncology, 2013, 31, 3565-3571.	1.6	43
64	Intermittent and continuous androgen deprivation did not differ for mortality after radiotherapy for prostate cancer. Annals of Internal Medicine, 2013, 158, JC9.	3.9	1
65	Risk assessment to guide prostate cancer screening decisions: a cost-effectiveness analysis. Medical Journal of Australia, 2013, 198, 546-550.	1.7	20
66	Why Is Management of Cancer Pain Still a Problem?. Journal of Clinical Oncology, 2012, 30, 1907-1908.	1.6	16
67	Individual patient meta-analysis: Taxane plus anthracycline reduces mortality from early breast cancer. Annals of Internal Medicine, 2012, 156, JC6.	3.9	2
68	Bisphosphonates and other bone agents for breast cancer. , 2012, , CD003474.		98
69	Lung cancer clinicians' preferences for adjuvant chemotherapy in non-small-cell lung cancer: What makes it worthwhile?. Lung Cancer, 2011, 72, 213-218.	2.0	17
70	Patient-reported outcomes of prostate high-dose-rate brachytherapy boost comparing an outpatient and inpatient protocol: A two-center chronologic cohort study. Brachytherapy, 2011, 10, 454-460.	0.5	3
71	Patients' experiences of high-dose-rate brachytherapy boost for prostate cancer using an inpatient protocol. Brachytherapy, 2011, 10, 395-400.	0.5	6
72	Thinking and Talking About Life Expectancy in Incurable Cancer. Seminars in Oncology, 2011, 38, 380-385.	2.2	25

#	ARTICLE	IF	CITATIONS
73	Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 4498-4504.	1.6	131
74	Life After Adjuvant Chemotherapy for Breast Cancer: The News Is Mostly Good. <i>Journal of Clinical Oncology</i> , 2011, 29, 1092-1093.	1.6	0
75	How Long Have I Got? Estimating Typical, Best-Case, and Worst-Case Scenarios for Patients Starting First-Line Chemotherapy for Metastatic Breast Cancer: A Systematic Review of Recent Randomized Trials. <i>Journal of Clinical Oncology</i> , 2011, 29, 456-463.	1.6	122
76	A Randomized Controlled Trial of a Standardized Educational Intervention for Patients with Cancer Pain. <i>Journal of Pain and Symptom Management</i> , 2010, 40, 49-59.	1.2	62
77	Comparison of Two Standard Chemotherapy Regimens for Good-Prognosis Germ Cell Tumors: Updated Analysis of a Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1253-1262.	6.3	64
78	Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 3191-3198.	1.6	370
79	Certain Death in Uncertain Time: Informing Hope by Quantifying a Best Case Scenario. <i>Journal of Clinical Oncology</i> , 2010, 28, 2802-2804.	1.6	44
80	Patients'™ preferences for chemotherapy in non-small-cell lung cancer: A systematic review. <i>Lung Cancer</i> , 2010, 69, 141-147.	2.0	55
81	Meta-analysis provides evidence-based effect sizes for a cancer-specific quality-of-life questionnaire, the FACT-G. <i>Journal of Clinical Epidemiology</i> , 2010, 63, 270-281.	5.0	46
82	Are Cancer Drugs Less Likely to be Recommended for Listing by the Pharmaceutical Benefits Advisory Committee in Australia?. <i>Pharmacoeconomics</i> , 2010, 28, 463-475.	3.3	47
83	Students'™ PEARLS: successfully incorporating evidence-based medicine in medical students'™ clinical attachments. <i>Annals of Internal Medicine</i> , 2009, 150, JC4.	3.9	2
84	Reply to A.D. Sasse et al. <i>Journal of Clinical Oncology</i> , 2009, 27, e254-e254.	1.6	0
85	Students' PEARLS: successfully incorporating evidence-based medicine in medical students' clinical attachments. <i>Evidence-Based Medicine</i> , 2009, 14, 98-99.	0.6	7
86	Duration of Chemotherapy for Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Trials. <i>Journal of Clinical Oncology</i> , 2009, 27, 3277-3283.	1.6	193
87	Identification of Candidate Biomarkers of Therapeutic Response to Docetaxel by Proteomic Profiling. <i>Cancer Research</i> , 2009, 69, 7696-7703.	0.9	94
88	Comparing patients'™ and clinicians'™ assessment of outcomes in a randomised trial of sentinel node biopsy for breast cancer (the RACS SNAC trial). <i>Breast Cancer Research and Treatment</i> , 2009, 117, 99-109.	2.5	14
89	Deriving a Patient-Based Utility Index from a Cancer-Specific Quality of Life Questionnaire. <i>Value in Health</i> , 2009, 12, 800-807.	0.3	11
90	Preliminary Validation of an Optimally Weighted Patient-Based Utility Index by Application to Randomized Trials in Breast Cancer. <i>Value in Health</i> , 2009, 12, 967-976.	0.3	4

#	ARTICLE	IF	CITATIONS
91	Comparing patients' and their partners' preferences for adjuvant chemotherapy in early breast cancer. Patient Education and Counseling, 2008, 72, 239-245.	2.2	21
92	Assessment of health-related quality of life and patient benefit as outcome measures for clinical trials in hepatocellular carcinoma. Asia-Pacific Journal of Clinical Oncology, 2008, 4, 55-67.	1.1	3
93	Validity, Responsiveness, and Minimal Important Difference for the SF-6D Health Utility Scale in a Spinal Cord Injured Population. Value in Health, 2008, 11, 680-688.	0.3	43
94	Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial. Lancet Oncology, The, 2007, 8, 603-612.	10.7	127
95	Quality of life and adjuvant systemic therapy for early-stage breast cancer. Expert Review of Anticancer Therapy, 2007, 7, 1123-1134.	2.4	28
96	Psychosocial factors and patients' preferences for adjuvant chemotherapy in early breast cancer. Psycho-Oncology, 2007, 16, 48-59.	2.3	46
97	Predicting the Toxicity of Weekly Docetaxel in Advanced Cancer. Clinical Pharmacokinetics, 2006, 45, 611-622.	3.5	32
98	Prognostic factors in patients with recently diagnosed incurable cancer: a systematic review. Supportive Care in Cancer, 2006, 14, 999-1011.	2.2	121
99	Measuring men's opinions of prostate needle biopsy. ANZ Journal of Surgery, 2005, 75, 662-664.	0.7	23
100	Use of tamoxifen in advanced-stage hepatocellular carcinoma. Cancer, 2005, 103, 1408-1414.	4.1	54
101	What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile?. Lancet Oncology, The, 2005, 6, 581-588.	10.7	59
102	Health Status Rated With the Medical Outcomes Study 36-Item Short-Form Health Survey After Spinal Cord Injury. Archives of Physical Medicine and Rehabilitation, 2005, 86, 2290-2295.	0.9	63
103	Bisphosphonates for breast cancer. , 2005, , CD003474.		205
104	Assessing Quality of Life During Chemotherapy for Pleural Mesothelioma: Feasibility, Validity, and Results of Using the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire and Lung Cancer Module. Journal of Clinical Oncology, 2004, 22, 3172-3180.	1.6	91
105	The benefits and costs of tamoxifen for breast cancer prevention. Australian and New Zealand Journal of Public Health, 2003, 27, 34-40.	1.8	22
106	Fulvestrant: spreading the word, but not too thinly. Lancet, The, 2003, 362, 1254.	13.7	2
107	Evidence-based medicine: useful tools for decision making. Medical Journal of Australia, 2001, 174, 248-253.	1.7	75
108	Convergent Discriminative, and Predictive Validity of the Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) Assessment and Comparison with Analogous Scales From the EORTC QLQ-C30 and a Trial-Specific Module. Journal of Clinical Epidemiology, 1999, 52, 653-666.	5.0	59

#	ARTICLE	IF	CITATIONS
109	Responsiveness to Change in Health-Related Quality of Life in a Randomized Clinical Trial: A Comparison of the Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) with Analogous Scales from the EORTC QLQ-C30 and a Trial Specific Module. <i>Journal of Clinical Epidemiology</i> , 1998, 51, 137-145.	5.0	72